Terms: = Gastric cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
239 results:
1. A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.
Garmezy B; Borad MJ; Bahleda R; Perez CA; Chen LT; Kato S; Oh DY; Severson P; Tam BY; Quah CS; Harding JJ
Cancer Res Commun; 2024 Apr; 4(4):1165-1173. PubMed ID: 38602417
[TBL] [Abstract] [Full Text] [Related]
2. Circular RNA circTATDN3 promotes the Warburg effect and proliferation in colorectal cancer.
Lin J; Zhong W; Lyu Z; Peng J; Rong Y; Zeng K; Lai J; Wu D; Wang J; Li Y; Zheng J; Zhang J; Pan Z
Cancer Lett; 2024 May; 589():216825. PubMed ID: 38548218
[TBL] [Abstract] [Full Text] [Related]
3. cancer-associated fibroblasts promote gastric cancer cell proliferation by paracrine FGF2-driven ribosome biogenesis.
Li D; Huang P; Xia L; Leng W; Qin S
Int Immunopharmacol; 2024 Apr; 131():111836. PubMed ID: 38479160
[TBL] [Abstract] [Full Text] [Related]
4. Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK.
McCarthy G; Young K; Madin-Warburton M; Mantaian T; Brook E; Metcalfe K; Mikelson J; Xu R; Seyla-Hammer C; Aguiar-Ibáñez R; Amonkar M
J Med Econ; 2024; 27(1):279-291. PubMed ID: 38293714
[TBL] [Abstract] [Full Text] [Related]
5. FGF2 drives osteosarcoma metastasis through activating fgfr1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
6. Ranitidine as an adjuvant regulates macrophage polarization and activates CTLs through the PI3K-Akt2 signaling pathway.
Li C; Wang S; Ma X; Wang T; Lu R; Jia X; Leng Z; Kong X; Zhang J; Li L
Int Immunopharmacol; 2023 Mar; 116():109729. PubMed ID: 37800555
[TBL] [Abstract] [Full Text] [Related]
7. Expression of B7-H3 and TIM-3 in gastric-type endocervical adenocarcinoma: prevalence, association with PD-L1 expression, and prognostic significance.
Sun Y; Zhou X; Lucas E; Chen L; Zhang H; Chen H; Zhou F
J Pathol Clin Res; 2024 Jan; 10(1):e345. PubMed ID: 37798754
[TBL] [Abstract] [Full Text] [Related]
8. Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs.
Pace A; Scirocchi F; Napoletano C; Zizzari IG; Po A; Megiorni F; Asquino A; Pontecorvi P; Rahimi H; Marchese C; Ferretti E; Nuti M; Rughetti A
J Transl Med; 2023 Sep; 21(1):626. PubMed ID: 37715207
[TBL] [Abstract] [Full Text] [Related]
9. The utility of H2 receptor antagonists in preventing infusion-related reactions to paclitaxel chemotherapy.
Tsang C; Robinson J; Wheatley-Price PF; Brule SY; Moore SM
Cancer; 2023 Dec; 129(23):3815-3819. PubMed ID: 37665180
[TBL] [Abstract] [Full Text] [Related]
10. ADT-OH synergistically enhanced the antitumor activity of celecoxib in human colorectal cancer cells.
Xu H; Li P; Ma H; Tan Y; Wang X; Cai F; Xu J; Sun H; Zhuang H; Hua ZC
Cancer Med; 2023 Aug; 12(16):17193-17211. PubMed ID: 37492969
[TBL] [Abstract] [Full Text] [Related]
11. Futibatinib, an Irreversible fgfr1-4 Inhibitor for the treatment of FGFR-Aberrant Tumors.
Javle M; King G; Spencer K; Borad MJ
Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
[TBL] [Abstract] [Full Text] [Related]
12. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
Lutz MS; Zekri L; Weßling L; Berchtold S; Heitmann JS; Lauer UM; Jung G; Salih HR
Front Immunol; 2023; 14():1163136. PubMed ID: 37122707
[TBL] [Abstract] [Full Text] [Related]
13. The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo.
McSheehy PMJ; Forster-Gross N; El Shemerly M; Bachmann F; Roceri M; Hermann N; Spickermann J; Kellenberger L; Lane HA
Anticancer Drugs; 2023 Apr; 34(4):532-543. PubMed ID: 36729959
[TBL] [Abstract] [Full Text] [Related]
14. Long-term vonoprazan administration causes gastric fundic gland-type hyperplastic polyps and chronic bleeding.
Goto C; Okimoto K; Matsusaka K; Matsumura T; Akizue N; Ohta Y; Taida T; Saito K; Kato J; Kato N
Clin J Gastroenterol; 2023 Apr; 16(2):159-163. PubMed ID: 36586091
[TBL] [Abstract] [Full Text] [Related]
15. The dual FAK-HDAC inhibitor MY-1259 displays potent activities in gastric cancers in vitro and in vivo.
Song J; Liu X; Zhang YF; Tian XY; Deng MY; Huang CZ; Zhang SY
Bioorg Chem; 2023 Feb; 131():106328. PubMed ID: 36542986
[TBL] [Abstract] [Full Text] [Related]
16. BMP2 inhibits cell proliferation by downregulating EZH2 in gastric cancer.
Chen Z; Yuan L; Li X; Yu J; Xu Z
Cell Cycle; 2022 Nov; 21(21):2298-2308. PubMed ID: 35856444
[TBL] [Abstract] [Full Text] [Related]
17. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
Shao X; Zhan S; Quan Q; Shen Y; Chen S; Zhang X; Li R; Liu M; Cao L
Int Immunopharmacol; 2022 Sep; 110():108988. PubMed ID: 35777267
[TBL] [Abstract] [Full Text] [Related]
18. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.
Gerratana L; Movarek M; Wehbe F; Katam N; Mahalingam D; Donahue J; Shah A; Chae YK; Mulcahy M; Tsarwhas D; Villaflor V; Kalyan A; Hussein M; Patel J; Chandra S; Platanias LC; Gradishar W; Cristofanilli M; Behdad A
JCO Precis Oncol; 2022 Jun; 6():e2100289. PubMed ID: 35772051
[TBL] [Abstract] [Full Text] [Related]
19. Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer.
Wu X; Liu Z; Gan C; Wei W; Zhang Q; Liu H; Que H; Su X; Yue L; He H; Ouyang L; Ye T
Bioorg Chem; 2022 Oct; 127():105965. PubMed ID: 35759882
[TBL] [Abstract] [Full Text] [Related]
20. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
[TBL] [Abstract] [Full Text] [Related]
[Next]
